NEW YORK, NY / ACCESSWIRE / March 29, 2019 / Stock Market Press (SMP) highlights DirectView Holdings, Inc (OTC PINK: DIRV) cannabis security experts, with premium booth #532 at the 2019 Cannabis Conference, expand their partnerships with Integrity General Contractors out of Dallas-Fort Worth, Texas. Additional companies covered in this spotlight include Canopy Growth Corporation (NYSE: CGC) and Tilray, Inc. (NASDAQ: TLRY)

Texas is in the midst of expanding their medical marijuana program and recently voted to reduce the recreational penalties. (Source: https://tinyurl.com/yxqnyfa6) This will create significant opportunities for DirectView Holdings, Inc. (OTC PINK: DIRV) and Integrity General Contractors’ partnership in the existing construction, new construction and security/surveillance marketplace.

Keep up with our latest alerts by joining the Stock Market Press newletter

The 2019 Cannabis Conference in Las Vegas, NV, Apr 1-3, will bring the industry players together to discuss opportunities and challenges facing the cannabis market. DirectView Holdings, Inc. (OTC PINK: DIRV) will present their custom-tailored and proprietary cannabis industry surveillance, security, and safety solutions.

Every state has different security requirements and DirectView Holdings, Inc. (OTC PINK: DIRV) keeps their complete turnkey solutions up to spec as the laws change, saving their clients time, money and legal hassles while maintaining quality control.

The whole cannabis industry is going through major mergers and acquisitions. One such company, Canopy Growth Corporation (NYSE: CGC), continues to acquire interest or complete ownership in existing and startup companies. Security is a main concern for them and DirectView Holdings, Inc. (OTC PINK: DIRV) is a perfect candidate to handle it all end to end.

The acquisition deal with Manitoba Harvest puts Tilray, Inc. (NASDAQ: TLRY) into a position to tap into an extensive US distribution network and the new CBD products from Manitoba Harvest. CVS just announced they will be carrying CBD products, opening up a huge new retail market for companies like Tilray, Inc. (NASDAQ: TLRY) and requiring additional security which DirectView Holdings, Inc. (OTC PINK: DIRV) can provide.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005
info@stockmarketpress.com
https://twitter.com/PressStock

Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/

SOURCE: Stock Market Press

ReleaseID: 540441

CHANTILLY, VA / ACCESSWIRE / March 29, 2019 / Novume Solutions, Inc. (NASDAQ: NVMM) announced today that its Board of Directors approved changing the company’s name to Rekor Systems, Inc. The planned name change is a result of the company’s recent acquisition of assets of OpenALPR Technology, Inc. and increased focus on technology products and services. The company recently renamed its subsidiary from Brekford Traffic Safety, Inc. to Rekor Recognition Systems, Inc. The line of hardware and software products and services offered by Rekor Recognition Systems, Inc. is powered by OpenALPR software, which uses artificial intelligence to improve the performance of automated license plate readers. The line was designed to assist law enforcement agencies in improving public safety and has commercial uses in automated parking management, electronic tolling, traffic flow management, supply chain logistics and customer loyalty. To complement the planned name change to Rekor Systems, Inc., Novume has applied to the Nasdaq Capital Market to change its trading symbol to “REKR.”

Beginning with the first quarter of 2019, the company also plans to change its operating and reportable segments from one segment to two segments. The two segments are expected to reflect that company’s focus on both technology products and services and professional services.

About Novume Solutions, Inc.

The company provides products and services to both government and private sector clients, with an emphasis on public safety, risk management and workforce solutions. For more information, please visit novume.com, or connect with us on Twitter, LinkedIn, or Facebook.

Forward-Looking Statements

This press release includes statements concerning Novume Solutions, Inc. and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” by the negative of these terms or by other similar expressions. You are cautioned that such statements are subject to many risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual circumstances, events or results may differ materially from those projected in the forward-looking statements, particularly as a result of various risks and other factors identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events, or otherwise.

Media Contact:

Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

Investor Contact:

Robert Berman
Novume Solutions
ir@novume.com

SOURCE: Novume Solutions, Inc.

ReleaseID: 540442

ANN ARBOR, MI / ACCESSWIRE / March 29, 2019 / ENDRA Life Sciences Inc. (”ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has reported initial findings on the first human Thermo Acoustic Enhanced Ultrasound (TAEUS) feasibility study of liver fat on 25 subjects at the Robarts Research Institute.

To date, 25 healthy volunteer study subject TAEUS data sets have been analyzed and compared with quantitative MRI fat fraction measurements, acquired for each subject, along with other indicators such as Body Mass Index (BMI) and abdominal fat thickness as measured by traditional ultrasound.

Study Demographics

21 study subjects had less than 6% liver fat fraction by MRI, which is clinically categorized as ‘healthy/normal’ range liver fat fraction. The other four study subjects fell into the 8%-22.4% fat fraction, typically categorized as ‘mild’ NAFLD. No study subject was eliminated from the analysis, and no subjects were yet enrolled in the ‘moderate’ (26%-37%) or ‘severe’ (>37%) liver fat fraction grades of NAFLD.

Findings

The correlation between thermoacoustic measurements of ENDRA’s reference design and the percent fat fraction by MRI had an R2 of 0.61, with a standard error of the mean of 2.98%.

In contrast, the correlations between BMI (Body Mass Index) with MRI fat fraction was only 0.19 and the correlation of abdominal fat thickness (as determined by ultrasound) with MRI fat fraction was 0.31.

Interestingly, some subjects with ‘mild’ fatty liver (based on MRI fat fraction) were incorrectly classified by conventional (non-TAEUS) ultrasound assessment as normal or severe, while TAEUS measures showed close agreement with MRI fat fraction in those subjects.

Next Steps

The next phase of feasibility studies will aim to add study subjects that stratify the range of liver fat fraction seen in mild, moderate and severe fatty liver, that ranges from 6% – 50% liver fat by MRI. Those findings of 50 subjects may vary significantly from these initial data.

ENDRA will also be participating (Booth #514) in the American Institute of Ultrasound in Medicine (AIUM) Conference in Orlando, Florida on April 6-10, to build relationships and discuss the data with an estimated 1,400 clinicians, sonographers and scientists attending the meeting.

”We are pleased with the initial findings from our proprietary reference design and it is very encouraging to see a correlation to MRI on such a small group of subjects right out of the gate,” said ENDRA Life Sciences CEO, Francois Michelon. ”We look forward to following up with additional findings in the months to come after we complete data collection on 50 subjects.”

”In addition to the Robarts study, we plan to initiate several additional North American and European clinical studies in 2019 to build a strong base of clinical data to support our initial commercialization efforts in Europe, following an anticipated CE Mark,” said ENDRA Life Sciences CTO, Michael Thornton.

ENDRA’s investigational TAEUS technology, which uses RF energy to enhance ultrasound, is designed to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI — at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver for early detection and monitoring of NAFLD, which affects over one billion people globally.

The Study Investigators at Robarts Research Institute have registered the study on the National Institute of Health database of global clinical studies here. Robarts Research Institute will continue to update the status of the study as it progresses and as is customary, the study duration was set to 12 months since initiation in September 2018 to allow adequate time for final data analysis, audit, and report compilation. For more information on ENDRA’s TAEUS technology, please see the November 2018 white paper titled: ‘Thermoacoustic Imaging: A Novel Method for Quantifying Fat in NAFLD’ here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI – at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA’s goal is to bring new capabilities to ultrasound – thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

About NonAlcoholic Fatty Liver Disease (NAFLD)

NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

Forward-Looking Statements

All statements in this release that are not based on historical fact are ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding the results of pending human studies and nature of the data obtained from such studies; the adequacy of protections afforded to us by the patents that we own and the success we may have in, and the cost to us of, maintaining, enforcing and defending those patents; expectations concerning ENDRA’s ability to secure regulatory approvals; estimates of the timing of future events and achievements, including obtaining a CE Mark and commercializing the TAEUS device; and expectations concerning ENDRA’s business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA’s filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.

ReleaseID: 540497

VANCOUVER, BC / ACCESSWIRE / March 29, 2019 / MGX Minerals Inc. (”MGX” or the ”Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) and engineering partner PurLucid
Treatment Solutions (”PurLucid”) are pleased to provide the following update on commercial-scale deployment of its first two contracted wastewater treatment systems.

The first contracted system is now fully manufactured and being commissioned at an oilsands SAGD operation in Alberta to process evaporator blowdown water (EBD) and is expected to be operational shortly. Fabrication and deployment of the second contracted wastewater treatment system is scheduled for June and will also be deployed to an oilsands SAGD operator in Alberta. Both systems are capable of processing 10m3 per hour and upon completion of test and optimization phase, the customers will pay a fixed processing fee. The Company and PurLucid anticipate generating revenue of C$2.0 million in 2019 during the ramp up period from the first two contracted operations. Contracts are currently being negotiated for additional wastewater treatment systems and are expected to be finalized shortly.

The Company has issued a total of 520,000 common shares as consideration for services rendered to consultants of the Company. The shares are subject to a four-month hold period. Additionally, the Company has granted an aggregate of 3,825,000 options to certain consultants, directors and officers. The options are exercisable at a price of $0.39 per share for a period of two years from the date of grant.

Rapid Lithium Brine Extraction Technology

MGX and PurLucid developed a rapid lithium extraction technology eliminating or greatly reducing the physical footprint and investment in large, multi-phase, lake sized, lined evaporation ponds, as well as enhancing the quality of extraction and recovery across a complex range of brines as compared with traditional solar evaporation. This technology is applicable to petrolithium (oil and gas wastewater), natural brine and other brine sources such as lithium-rich mine and industrial plant wastewater.

About PurLucid

PurLucid’s exclusively licensed and patented nanoflotation technology was designed specifically for oilfield environments. The technology separates impurities from oil and gas wastewater and produces clean water as a final product. This allows for the recycling or controlled release of oilfield wastewater and reduces or eliminates downhole and associated transportation costs. Water handling costs are one of the largest operating costs in the oilfield and oilsands operations today. Learn more at www.purlucid.com. MGX has the right to acquire up to a 100% interest in PurLucid through successive investments.

About MGX Minerals

MGX Minerals is a diversified Canadian resource and technology company with interests in global advanced material, energy and water assets. Learn more at www.mgxminerals.com.

Contact Information

Jared Lazerson

President and CEO

Telephone: 1.604.681.7735

Web: www.mgxminerals.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements (collectively “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: “believe”, “expect”, “anticipate”, “intend”, “estimate”, “potentially” and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to the Company’s public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company’s profile on SEDAR at www.sedar.com.

SOURCE: MGX Minerals Inc.

ReleaseID: 540506

BOCA RATON, FL / ACCESSWIRE / March 29, 2018 / Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the year ended December 31, 2018.

Highlights

Vycor has been working on improving how its VBAS integrates with the most common Image Guidance System (”IGS”) pointers on the market; the first phase of this was completed and the Company started shipping its enhanced VBAS model at the end of September. Vycor took the decision in February 2018, based on surgeon feedback, to cease shipment of its previous model. As a result, manufacturing of the enhanced model needed to be accelerated and this caused some delays, which resulted in lost revenue through the first six months of the year, at which point sales had decreased by 15% over the same period in 2017. However, as the delays were reversed and with positive surgeon adoption of the newly enhanced VBAS, sales accelerated in the second half of the year by 40% compared to the same period in 2017, and actually ended the year with revenues increasing 11% over 2017.
The second phase of development of the VBAS IGS device is now well advanced with product being manufactured for further testing and regulatory submission, and we will also be exploring with surgeons and complementary product manufacturers additional selected development work targeted at increasing the ease and applicability of our VBAS range.
NovaVision currently has approximately 260 patients undergoing its therapies in the US and internationally. Patient compliance continues to be strong, with 75% of patients who have started since the introduction of the Internet model completing the full 6 months of VRT, and over 30% of patients extending their therapy period beyond 6 months. NovaVision has also placed its Professional Model with 17 clinics or rehabilitation centers since it started the soft marketing of this model.
Under Vycor’s ownership, NovaVision has gone from a business with a prototype therapy to one with a broad suite of proven patient and professional therapies and diagnostic products, utilizing a flexible range of delivery technologies. The therapies are protected by 45 patents and have a significant body of clinical data that is being added to and which demonstrates their efficacy. Management has made clear over the last year, however, that given the company’s resources, and the large size and diversity of NovaVision’s end markets, it believes the most efficient way to fulfill NovaVision’s potential is through partnerships. The range of alternatives for NovaVision could comprise distribution and marketing partnerships, licensing, merger or sale.

Management Commentary

”The enhanced VBAS model that we released in the fourth quarter of 2017 has been well received by the market” said Peter Zachariou, CEO of Vycor Medical. ”The strong performance of the division in the second half demonstrates that the IGS development work we are carrying out for our VBAS product will position the business well for the future, and we look forward to completing that development during 2019, subject to regulatory clearances”.

”Our stated focus on the reduction of cash burn has continued. Our Cash Operating Loss [1] despite our investment in manufacturing and new products, reduced to $207,000 for the year compared to $463,000 for 2017, and the Company generated a Cash Operating Profit1 in both the third and fourth quarters of the year.”

Year ended December 31, 20178 Financial Results

Revenue totaled $1,509,000 in the year ended December 31, 2018, as compared to $1, 385,000 for the prior year, an increase of 9%. Vycor Medical’s revenue increased by $133,000 or 11% and generated a gross margin of 88% compared to 83% in 2017. NovaVision recorded revenues of $198,019 for the year ended December 31, 2018, a decrease of $8,889 from 2017, and gross margin of 91%, compared to 89% for 2017.

Operating Expenses in the year ended December 31, 2018 totaled $2,657,000 as compared to $2,470,000 in 2017, of which $308,000 was in respect of the impairment charge against NovaVision’s assets. Cash Operating Expenses [2] were $1,547,000 as compared to $1,620,000. Operating Loss was $1,318,000, compared to $1,313,000 for 2017, and Cash Operating Loss2 was $207,000, as compared to $463,000, a reduction of 55%.

Net Loss for the year ended December 31, 2018 was $1,379,000 as compared to $1, 477,000 in 2017.

About Vycor Medical, Inc.

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Non-GAAP Measures

We make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures that exclude Depreciation, Amortization and non-cash Stock Compensation.

We believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

VYCOR MEDICAL, INC.
Consolidated Statements of Comprehensive Loss

For the Twelve Months Ended December 31,

2018

2017

Revenue

$1,509,330

$1,384,971

Cost of Goods
Sold

169,598

201,363

Gross Profit

1,339,732

1,183,608

Operating
expenses:

Research and development

–

3,015

Depreciation and Amortization

166,386

275,416

Selling, general and administrative

2,183,505

2,185,769

Impairment of assets

307,576

–

Total Operating expenses

2,657,467

2,464,200

Operating
loss

(1,317,735)

(1,280,592)

Other income
(expense)

Interest expense: Other

(48,800)

(48,523)

Interest expense: Related Party

(11,434)

(679)

Gain (loss) on foreign currency exchange

(1,387)

1,392

Gain (loss) on other income and expense

0

4,028

Warrant issuance expense

–

(120,788)

Total Other Income (expense)

(61,621)

(164,570)

Loss Before
Credit for Income Taxes

(1,379,356)

(1,445,162)

Credit for income taxes

–

–

Net Loss

(1,379,356)

(1,445,162)

Preferred stock dividends

(324,970)

(324,970)

Net Loss
available to common shareholders

(1,704,326)

(1,770,132)

Comprehensive
Loss

Foreign Currency Translation Adjustment

(2,832)

5,278

Comprehensive Loss

(1,707,158)

(1,764,854)

Net Loss Per
Share

Basic and diluted

($0.08)

($0.10)

Weighted
Average Number of Shares Outstanding – Basic and Diluted

21,599,118

18,373,355

Reconciliation
of Cash Operating Expenses and Cash Operating Loss Before
Depreciation,
Amortization and Other Non-Cash Items

For the Twelve Months Ended December 31,

2018

2017

GAAP Operating Expenses

(2,657,467)

(2,470,400)

Non-cash depreciation

127,020

127,899

Non-cash amortization of intangible assets

50,331

162,076

Non-cash stock-based compensation

625,625

559,972

Impairment of assets

307,576

–

Non GAAP Cash Operating
Expenses

(1,546,915)

(1,620,453)

GAAP Operating Loss

(1,317,735)

(1,312,563)

Non-cash depreciation

127,020

127,899

Non-cash amortization of intangible assets

50,331

162,076

Non-cash stock-based compensation

625,625

559,972

Impairment of assets

307,576

–

Non GAAP Operating loss
Before

Depreciation and
Amortization

(207,183)

(462,616)

Vycor Medical, Inc. Contact:

951 Broken Sound Parkway NW
Suite 320
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

[1] Operating Profit/Loss before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

[2] Operating Expenses before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

SOURCE: Vycor Medical, Inc.

ReleaseID: 540490

PHILLIPSBURG, NJ / ACCESSWIRE / March 29, 2019 / Edison Nation, Inc. (NASDAQ: EDNT), a full-service product development firm, has announced new initiatives to escalate market presence to a wider audience of aspiring inventors to drive higher success potential for ideas to be commercialized. These new marketing initiatives include the relaunch of the Emmy award-winning TV show, “Everyday Edisons,” and debuting a new design for the front-end of their open innovation platform website, www.EdisonNation.com.

Edison Nation’s online innovation platform has virtually connected innovators with companies to bring new products to market since 2007, partnering with over 140,000 innovators from around the world which have resulted in over $250 million in retail sales to-date. The recently updated corporate website, www.EdisonNation.com, features the newly minted Edison Nation branding and offers a clean, simplified design with improved functionality for front-end users. Visitors can effortlessly obtain essential information regarding the platform’s services, while easily gaining access to enriching content and resources through the blog and forums.

“Over the last couple of months, we’ve slowly introduced the new branding for Edison Nation, but the launch of this new website design makes it official,” said Chris Ferguson, CEO of Edison Nation, Inc. “With our platform being online based, it is vital for us to keep a finger on the pulse and continue to modernize the platform to enhance the experience for our community of innovators, while at the same time, making sure the site is clear and user-friendly.”

The front-end redesign of the website is only phase 1 of Edison Nation’s commitment to provide a more enhanced virtual experience for users. Execution of the next phase-updating the back-end member’s user-portal to match the front-end design-is set to begin immediately. Phase 3, which is the development of an interactive mobile app, is scheduled for summer 2019.

In addition to the website revamp, Edison Nation is also relaunching the Emmy award-winning TV show, “Everyday Edisons.” Everyday Edisons is an inspirational reality TV series produced under license by Edison Nation, which chronicles the stories of first-time inventors as they launch their unique products into the marketplace in conjunction with the Edison Nation product development platform. The three-time Emmy and two-time Telly award-winning show originally aired for 5 seasons on PBS.

Edison Nation encourages investors to watch this sizzle, using password ENTV to find out more information.

In December 2018, Edison Nation entered into an agreement with a leading digital media services company to expand distribution of its Everyday Edisons TV series into key global markets. The agreement, which covers two existing 13-episode seasons, will include the creation of a professional voiceover-translation in German, French and Spanish and the subsequent release in Europe and the Middle East. The full seasons will also be available for viewing on select streaming platforms worldwide, such as Amazon Prime Video.

Chris Ferguson, CEO of Edison Nation, Inc., added: “The return of ‘Everyday Edisons’ is not only a strategic marketing effort, but it upholds Edison Nation’s commitment to continually deliver stimulating content to our community of inventors.”

About Edison Nation, Inc.

Edison Nation, Inc. is a vertically integrated innovation aggregation and full-service product development and manufacturing company, offering innovation sourcing, design, sales, fulfillment and shipping services. Edison Nation’s model is to provide a risk mitigated platform that connects innovators with companies to bring new products to market. For more information, please visit www.edisonnation.com.

Forward Looking Statements 

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the Company’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing the Company’s products in global markets, competition in the market for consumer products, any inability to raise capital to fund operations and service the Company’s debt.  Additional information that could lead to material changes in the Company’s performance is contained in its filings with the SEC. The Company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Investor Relations:

Greg Falesnik
Managing Director 
MZ North America
Direct: 949-385-6449
EDNT@mzgroup.us 

SOURCE: Edison Nation, Inc.

ReleaseID: 540495

Annual 10-K Filing for Marijuana and Cannabis M&A Company

SAN DIEGO, CA / ACCESSWIRE / March 29, 2019 / Mentor Capital, Inc. (OTCQX: MNTR) announced that it had filed its annual 10-K filing for the year December 31, 2018, with the Securities and Exchange Commission.

The Company reports that for the year ended December 31, 2018 Mentor had revenues of $5,281,533 and gross profit of $1,582,599 with a resulting net loss attributable to Mentor of ($409,161) or (1.8 cents) per share. This is an improvement from the year ended December 31, 2017 in which Mentor had revenues of $3,182,700 and gross profit of $1,107,045 with a resulting net loss attributable to Mentor of ($753,895) or (3.4 cents) per share.

The Mentor Capital, Inc. parent company has no non-affiliate debt and collected a net payment of $1,758,949 on January 23, 2018 in satisfaction of the Company’s judgment against Bhang Corporation. The Company raised $109,985 during the year ended December 31, 2018 from the issuance of Series Q preferred shares and the Company also raised $629,205 during the year ended December 31, 2018 under the authority of an 11 U.S.C. § 1145 order and $6,316 from warrant redemption fees at $0.10 per warrant from designees redeeming unexercised warrants that have been called but were not exercised timely. The Company invested $1,974,716 into cannabis-related companies during the year and the Company maintained a balance of cash of $1,470,574 at December 31, 2018 compared to $1,148,726 at December 31, 2017. The Company closed the year ended December 31, 2018 with a book value of $6,433,840 up from $6,346,613 at the end of 2017.

Mentor Capital, Inc. had 12,606 shareholders reported as of December 31, 2018, with 23,139,837 shares issued. At December 31, 2018, there were 87,456 Series B warrants outstanding with an exercise price of $0.11 per share, 6,252,954 Series D warrants outstanding with an exercise price of $1.60 per share, and 689,159 Series H warrants that are held by an investment bank at a $7.00 per share exercise price. No equity was granted to directors, insiders, consultants or investor relations firms in 2018. The Company’s shares finished the year at a closing price of $0.34 per share representing a market capitalization of $7,867,545 compared to a 2017 year-end closing price of $2.29 per share and a corresponding market capitalization of $52,244,708. As of March 28, 2019, the closing price of the Company’s shares was $0.47 with a corresponding market capitalization of approximately $10,875,723.

The Company is managed by Chairman, CEO, and director Chet Billingsley (66), who founded Mentor Capital first as an acquisition partnership in 1985 and was qualified as a Registered Investment Advisor. He received his undergraduate education at West Point before earning a master’s degree in Applied Physics at Harvard University. His early career was at General Electric. Treasurer, CFO, and director Lori Stansfield, CPA (59), was most recently Director of Audit Services for a regional CPA firm. She graduated Magna cum Laude in accounting and received a master’s degree in Marketing from the University of Colorado. Ms. Stansfield is certified as a public accountant in both Colorado and California. Secretary and director Robert Meyer (79), director and Audit Committee member Stan Shaul (54), and director and Audit Committee Chairman David Carlile (63) are independent directors, and each has been or is a business owner and major shareholder. Altogether, the directors and officers hold a 24.5% fully diluted interest in Mentor Capital with Mr. Billingsley’s interest reported at 17.96% on a fully diluted basis as of March 15, 2019.

The 10-K includes December 31, 2018 audited financials and can be referenced through the SEC’s EDGAR system at:

https://www.sec.gov/edgar/searchedgar/companysearch.html

Inputting the company name, Mentor Capital, Inc. or the Company’s CIK code which is 0001599117, will bring up the report. The 10-K can also be viewed at the Company’s website at the Investor’s Corner section under the SEC Filings tab.

About Mentor Capital: The Company seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives, to add protection for investors and to help incubate private cannabis companies. Additional important information for investors is presented at:

www.MentorCapital.com

This press release is neither an offer to sell, nor a solicitation of offers to purchase, securities.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as ”should,” ”could,” ”expects,” ”may,” ”intends,” ”seeks,” ”looks,” ”moves,” or ”plans” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales, problems securing the necessary financing to continue operations, problems involving continued illegality of cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, in recruiting knowledgeable personnel and in protecting intellectual property. Further information concerning these, and other risks is included in the Company’s Form 10-K filing which, along with other very important information about the Company, can be found here:

https://ir.mentorcapital.com/all-sec-filings

The Company undertakes no obligation to update or revise such forward-looking statements to reflect new information, events or circumstances occurring after the date of this press release.

For further information contact:

Mentor Capital, Inc.
Chet Billingsley, CEO
(760) 788-4700

SOURCE: Mentor Capital, Inc.

ReleaseID: 540500